Efficient tumor control of glioma and BrM was shown to depend on enhanced CD8+ T‐cell priming and recruitment to CNS lesions which synergized with ICB (Taggart et al,2018; Song et al,2020). This evidence concerns the gene CD8A and neoplasm.